149 related articles for article (PubMed ID: 11744474)
21. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
[TBL] [Abstract][Full Text] [Related]
22. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
Alexander BM; Chen MH; Carroll P; D'Amico AV
Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
Koppie TM; Shinohara K; Grossfeld GD; Presti JC; Carroll PR
J Urol; 1999 Aug; 162(2):427-32. PubMed ID: 10411051
[TBL] [Abstract][Full Text] [Related]
25. Cryosurgical ablation for prostate cancer: preliminary results of a new advanced technique.
Leibovici D; Zisman A; Siegel YI; Lindner A
Isr Med Assoc J; 2001 Jul; 3(7):484-7. PubMed ID: 11791412
[TBL] [Abstract][Full Text] [Related]
26. Rationale for a "male lumpectomy," a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up.
Onik G
Cardiovasc Intervent Radiol; 2008; 31(1):98-106. PubMed ID: 17593431
[TBL] [Abstract][Full Text] [Related]
27. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
28. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Shinohara K; Rhee B; Presti JC; Carroll PR
J Urol; 1997 Dec; 158(6):2206-9; discussion 2209-10. PubMed ID: 9366345
[TBL] [Abstract][Full Text] [Related]
29. Prostate cryoablation without an insertion kit using direct transperineal placement of ultrathin freezing probes.
Zisman A; Leibovici D; Siegel YI; Lindner A
Tech Urol; 2000 Mar; 6(1):34-6. PubMed ID: 10708146
[TBL] [Abstract][Full Text] [Related]
30. Prostate cryoablation: update 1998.
Schmidt JD; Doyle J; Larison S
CA Cancer J Clin; 1998; 48(4):239-53. PubMed ID: 9676539
[TBL] [Abstract][Full Text] [Related]
31. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
32. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature.
Nguyen PL; D'Amico AV; Lee AK; Suh WW
Cancer; 2007 Oct; 110(7):1417-28. PubMed ID: 17694553
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
34. Cryosurgical ablation of the prostate: high risk patient outcomes.
Prepelica KL; Okeke Z; Murphy A; Katz AE
Cancer; 2005 Apr; 103(8):1625-30. PubMed ID: 15747374
[TBL] [Abstract][Full Text] [Related]
35. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
36. Impact of disease burden on cryoablation prostate-specific antigen outcomes.
Levy DA; Li J; Jones S
Urology; 2010 Feb; 75(2):478-81. PubMed ID: 19963251
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
Hong SK; Park HZ; Lee WK; Kim DS; Lee JS; Doo SH; Jeong SJ; Yoon CY; Byun SS; Lee SE
Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
[TBL] [Abstract][Full Text] [Related]
38. Primary cryoablation nadir prostate specific antigen and biochemical failure.
Levy DA; Pisters LL; Jones JS
J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
[TBL] [Abstract][Full Text] [Related]
39. Transrectal ultrasound-guided transperineal cryoablation in the treatment of prostate carcinoma: preliminary results.
Wieder J; Schmidt JD; Casola G; vanSonnenberg E; Stainken BF; Parsons CL
J Urol; 1995 Aug; 154(2 Pt 1):435-41. PubMed ID: 7541861
[TBL] [Abstract][Full Text] [Related]
40. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
Dhar N; Ward JF; Cher ML; Jones JS
BJU Int; 2011 Aug; 108(4):508-12. PubMed ID: 21722288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
